Navigation Links
Ground-breaking new insight into the development of Alzheimer's disease
Date:4/22/2008

Leuven, Belgium C According to estimates there are 85,000 Alzheimer patients in our country and approximately 20,000 new cases every year. This spectacular increase is due to the increasing ageing population. Unfortunately it is still unclear precisely which ageing process forms the basis of this spectacular rise in the occurrence of the disease. VIB scientists affiliated to K.U.Leuven have discovered an important molecular link between Alzheimer's disease and the development of the typical plaques in the brains of Alzheimer patients. This discovery is an important breakthrough in the fundamental research into the cause of Alzheimer's disease.

Alzheimer's disease: a growing problem

Alzheimer's disease, a neurodegenerative disease that slowly and gradually destroys brain cells, is the most common form of dementia in the Western world. The way in which it affects the memory and mental functioning makes it one of the most frightening disorders. Over the last 15 years the amount of research worldwide into this still incurable disease has grown considerably: faster diagnosis of the disease and better treatment are essential!

Amyloid plaques and Alzheimer's disease

Alzheimer's disease is associated with amyloid plaques C i.e. abnormal accumulations of protein fragments C that form in the brain cells. A few years ago Bart De Strooper and other researchers unravelled the process by which these plaques develop in the familial form of Alzheimer's disease (less common form). -secretase, which cuts proteins at a specific location C plays an important role here. Sometimes the secretase cuts in the wrong place, which results in a by-product and thus the formation of plaques. In the most common form of the disorder the same sort of plaques are found, but there is still little known about their development mechanism.

BACE1 or A-secretase

In patients with the most common form of Alzheimer's disease the brain cells show an increase in the protein BACE1 or A-secretase. VIB researcher Sabastien Hubert and colleagues, under the direction of Bart De Strooper and in collaboration with international experts, looked into the cause of this increase.

To this end the VIB researchers checked the expression profiles of certain microRNA's, i.e. the short pieces of RNA that regulate protein production. In patients where there was an increase in the BACE1 protein, there was a significant reduction in miR-29a and miR-29b-1. This observation suggests the possible role of certain miRNA's in the increase of BACE1 and in the formation of plaques in the brains of patients with Alzheimer's disease.

On the one hand this research raises hopes for a better diagnostic test. Timely prescription of certain medicines for Alzheimer's disease results after all in a better response, and thus a better quality of life for the patient. On the other hand there is the question of whether these microRNA's could in the future form the basis of a new drug.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects
3. Design-her Gals(TM) Announces the Ground-Breaking Virtual On-Line Walk for Wishes to Grant Dreams for Stage IV Breast Cancer Patients this Holiday Season Through Gal to Gal Foundation
4. John Hancocks EZ Route Post-Enrollment Education Program Wins 2008 Insight Award for Customer Advocacy in Financial Services
5. New studies add insights to infant feeding and obesity issue
6. Forecasting MDs prescriptions choice? Ask their patients, says Management Insights study
7. Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008
8. Shannon Brownlee, Author of Overtreated, to Keynote at Defined Healths 8th Annual Therapeutic Insight Conference
9. Insights on Paying for Boomers Care Needs in 20-40 Years Helped by New Report
10. 10th Annual Human Resources Conference, June 4-6: Sharing New Insights on Workforce Planning
11. Key factor in brain development revealed, offers insight into disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and ... Surgery Collaborative Residency Network. The platform is scheduled to launch in July 2016 ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology: